Total Payments
$13,310
2024 Payments
$1,163
Companies
43
Transactions
872
Medicare Patients
26,369
Medicare Billing
$3.1M
Payment Breakdown by Category
Food & Beverage$12,879 (96.8%)
Education$431.16 (3.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $12,879 | 859 | 96.8% |
| Education | $431.16 | 13 | 3.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,925 | 199 | $0 (2024) |
| Amgen Inc. | $1,843 | 127 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,614 | 87 | $0 (2024) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $1,151 | 84 | $0 (2024) |
| Amarin Pharma Inc. | $831.00 | 50 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $671.34 | 53 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $645.96 | 32 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $469.02 | 23 | $0 (2023) |
| Astellas Pharma US Inc | $389.41 | 8 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $366.87 | 22 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,163 | 79 | Novartis Pharmaceuticals Corporation ($370.01) |
| 2023 | $1,487 | 90 | Novartis Pharmaceuticals Corporation ($321.80) |
| 2022 | $1,739 | 116 | Amgen Inc. ($297.44) |
| 2021 | $2,199 | 148 | Amarin Pharma Inc. ($415.72) |
| 2020 | $1,443 | 97 | Amgen Inc. ($268.98) |
| 2019 | $1,506 | 92 | Amgen Inc. ($232.17) |
| 2018 | $1,467 | 110 | AstraZeneca Pharmaceuticals LP ($278.80) |
| 2017 | $2,307 | 140 | AstraZeneca Pharmaceuticals LP ($414.56) |
All Payment Transactions
872 individual payment records from CMS Open Payments — Page 1 of 35
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Philips North America LLC | (CK7) Extended Holter (Device) | Food and Beverage | Cash or cash equivalent | $14.71 | General |
| Category: Medical Device | ||||||
| 12/16/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $2.08 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $5.38 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/02/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $2.84 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 11/15/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $10.69 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/04/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $19.99 | General |
| Category: Cardiology | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $3.26 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/15/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $22.41 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/09/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: Cardiology | ||||||
| 10/02/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $17.24 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 10/02/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $13.97 | General |
| Category: Diabetes | ||||||
| 10/02/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $3.72 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/24/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: Cardiology | ||||||
| 09/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $25.53 | General |
| Category: DIABETES | ||||||
| 09/17/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.85 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/16/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $22.92 | General |
| Category: Cardiovascular | ||||||
| 09/13/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $30.50 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/11/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $21.71 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/06/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $1.11 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 09/05/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $7.89 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/27/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: Not Applicable | ||||||
| 08/27/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $6.10 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/15/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $24.64 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/14/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.22 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/14/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $15.04 | General |
| Category: General - Tachy_CRM | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 33 | 6,164 | 9,500 | $2.2M | $705,491 |
| 2022 | 33 | 6,568 | 10,168 | $2.3M | $760,748 |
| 2021 | 38 | 6,472 | 10,104 | $2.4M | $760,369 |
| 2020 | 42 | 7,165 | 11,185 | $2.7M | $824,080 |
Total Patients
26,369
Total Services
40,957
Medicare Billing
$3.1M
Procedure Codes
150
All Medicare Procedures & Services
150 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 1,024 | 1,832 | $282,108 | $157,665 | 55.9% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 297 | 297 | $362,934 | $90,204 | 24.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 654 | 668 | $260,355 | $87,309 | 33.5% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 503 | 800 | $300,250 | $69,097 | 23.0% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 267 | 1,068 | $122,823 | $46,581 | 37.9% |
| 78451 | Nuclear medicine study of heart muscle at rest and with stress and spect | Office | 2023 | 206 | 206 | $221,413 | $43,309 | 19.6% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 244 | 246 | $84,132 | $30,330 | 36.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 172 | 204 | $59,399 | $26,936 | 45.3% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 506 | 506 | $106,994 | $22,817 | 21.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 138 | 244 | $36,600 | $22,177 | 60.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 1,092 | 1,930 | $127,596 | $18,874 | 14.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 77 | 231 | $24,197 | $13,955 | 57.7% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 70 | 70 | $32,265 | $13,312 | 41.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 236 | 253 | $34,190 | $13,222 | 38.7% |
| 92928 | Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | Facility | 2023 | 20 | 26 | $22,987 | $10,225 | 44.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 83 | 83 | $18,600 | $9,216 | 49.5% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2023 | 54 | 55 | $19,951 | $7,082 | 35.5% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 69 | 177 | $7,726 | $3,759 | 48.7% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Office | 2023 | 39 | 96 | $9,216 | $2,404 | 26.1% |
| 93923 | Complete ultrasound study of arm and leg arteries | Office | 2023 | 27 | 27 | $6,237 | $2,334 | 37.4% |
| 92960 | External shock to heart to regulate heart beat | Facility | 2023 | 23 | 26 | $6,230 | $2,126 | 34.1% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 112 | 113 | $5,255 | $2,042 | 38.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 27 | 27 | $4,111 | $1,923 | 46.8% |
| 93297 | Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | Office | 2023 | 17 | 93 | $4,922 | $1,767 | 35.9% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 61 | 64 | $3,631 | $1,611 | 44.4% |
About Dr. Sadasiva Katta, M.D
Dr. Sadasiva Katta, M.D is a Cardiovascular Disease healthcare provider based in Huntsville, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1952381444.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sadasiva Katta, M.D has received a total of $13,310 in payments from pharmaceutical and medical device companies, with $1,163 received in 2024. These payments were reported across 872 transactions from 43 companies. The most common payment nature is "Food and Beverage" ($12,879).
As a Medicare-enrolled provider, Katta has provided services to 26,369 Medicare beneficiaries, totaling 40,957 services with total Medicare billing of $3.1M. Data is available for 4 years (2020–2023), covering 150 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Huntsville, AL
- Active Since 01/19/2006
- Last Updated 07/13/2022
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1952381444
Products in Payments
- ENTRESTO (Drug) $1,365
- Repatha (Biological) $1,363
- LifeVest (Device) $1,151
- BRILINTA (Drug) $933.07
- Vascepa (Drug) $831.00
- XARELTO (Drug) $671.34
- LEQVIO (Drug) $559.81
- Corlanor (Drug) $475.24
- JARDIANCE (Drug) $397.33
- ELIQUIS (Drug) $327.09
- Adempas (Drug) $299.22
- PRADAXA (Drug) $248.63
- FARXIGA (Drug) $225.90
- NEXLETOL (Drug) $216.70
- PRALUENT (Drug) $209.35
- Bidil (Drug) $159.53
- OPTIMIZER (Device) $134.49
- Impella (Device) $134.42
- WATCHMAN (Device) $119.20
- MULTAQ (Drug) $117.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Huntsville
Dr. Michael Butler, Md, MD
Cardiovascular Disease — Payments: $107,063
Cardiovascular Disease $107,063
Dr. Jay Dinerman, M.d, M.D
Cardiovascular Disease — Payments: $52,678
Cardiovascular Disease $52,678
Paul Tabereaux, Md, Mph, MD, MPH
Cardiovascular Disease — Payments: $38,822
Cardiovascular Disease $38,822
Dr. Enrique Velasquez, M.d, M.D
Cardiovascular Disease — Payments: $32,608
Cardiovascular Disease $32,608
Joshusa Valtos, Md, MD
Cardiovascular Disease — Payments: $21,858
Cardiovascular Disease $21,858
Dr. Vernon Hunter, M.d, M.D
Cardiovascular Disease — Payments: $12,613
Cardiovascular Disease $12,613